Drugs Made In America Acquisition Corp Units
DMAAU
5 hedge funds and large institutions have $5.77M invested in Drugs Made In America Acquisition Corp Units in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.48% less ownership
Funds ownership: 3.24% → 2.76% (-0.48%)
14% less capital invested
Capital invested by funds: $6.73M → $5.77M (-$966K)
38% less funds holding
Funds holding: 8 → 5 (-3)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$459K |
| 2 |
KC
Kryger Capital
London,
United Kingdom
|
+$40K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
-$1.06M |
| 2 |
TCM
Tuttle Capital Management
Riverside,
Connecticut
|
-$208K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$125K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$109K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KC
1
Kryger Capital
London,
United Kingdom
| $3.04M | +$40K | +3,810 | +1% |
|
|
WAM
2
Wolverine Asset Management
Chicago,
Illinois
| $1.37M | – | – | – |
|
|
CS
3
Clear Street
New York
| $957K | +$459K | +43,736 | +92% |
|
|
RCM
4
Robinson Capital Management
Grosse Pointe Farms,
Michigan
| $315K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $84.3K | -$109K | -10,364 | -56% |
|
|
RCM
6
Rivernorth Capital Management
West Palm Beach,
Florida
| – | -$1.06M | -102,372 | Closed |
|
|
TCM
7
Tuttle Capital Management
Riverside,
Connecticut
| – | -$208K | -20,000 | Closed |
|
|
8
Citadel Advisors
Miami,
Florida
| – | -$125K | -11,964 | Closed |
|
DMAAU Hedge Fund Activity: Q4 2025 in Review
5 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition Corp Units (DMAAU) for Q4 2025, worth a combined $5.77M — down 14% from $6.73M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of DMAAU and 0 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Clear Street, adding an estimated $459K. The largest seller was Rivernorth Capital Management, exiting entirely with an estimated $1.06M sold.
- 5 institutional investors held Drugs Made In America Acquisition Corp Units (DMAAU) as of Q4 2025, down from 8 in Q3 2025.
- Funds reported $5.77M of Drugs Made In America Acquisition Corp Units stock for Q4 2025, down 14% quarter-over-quarter.
- 0 funds opened new Drugs Made In America Acquisition Corp Units positions in Q4 2025 and 3 closed out, a net change of -3 holders.
- The largest Drugs Made In America Acquisition Corp Units buyer in Q4 2025 was Clear Street, an estimated $459K added.
- The largest Drugs Made In America Acquisition Corp Units seller in Q4 2025 was Rivernorth Capital Management, an estimated $1.06M sold.
Based on aggregated 13F filings for Q4 2025.